Grant: Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Direct Payment
$150,000.00
Will increasing APOBEC3G activity in the host cure HIV or cause cancer?
EF 2008-09
Résumé
The human APOBEC3G protein has the potential to stop the spread of the AIDS virus, HIV. APOBEC3G's mechanism of lethality involves causing mutations of guanine to adenine in the proviral DNA, which is termed hypermutation. This can occur so frequently that APOBEC3G literally kills the virus. However, the full potential of APOBEC3G is rarely realized in patients because HIV fights back with its own protein called Vif, which binds APOBEC3G and triggers its degradation. This Vif/APOBEC3G interaction would therefore be promising to alter in favour of the host for therapeutic potential. There is however one very important potential downside to such an approach: too much APOBEC3G activity may generate cancer-causing mutations. I therefore hypothesize that there is a critical threshold of APOBEC3G activity that is managed normally by host cells, but activity above this critical level would allow APOBEC3G to enter the host nucleus and cause mutations that could promote cancer. To test this hypothesis, I will express a range of APOBEC3G protein levels in cell lines and primary cells and monitor APOBEC3G cellular localization (nucleus vs. cytoplasm). I will also assess the induction of genomic mutations by monitoring reporter gene expression in cell lines for identification of mutations that nullify expression and by identifying the immortalization of primary cells. The proposed research will determine the possibility of saturating the cell's APOBEC3G threshold. If it can be saturated, we expect that with increased APOBEC3G expression, the level of APOBEC3G in the nucleus will also increase, as will the level of genomic mutations. Before novel treatment strategies for HIV are considered that alter APOBEC3G activity or levels, it is imperative to elucidate if increasing APOBEC3G expression will send the promutagenic protein to the nucleus and cause genomic mutations, to help ensure that we do not accidentally design drugs that give people cancer (but cure HIV).
Programme
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Bénéficiaire
Emplacement
Minnesota, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
177231
Name
Land Allison M
Region
Minnesota
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Will increasing APOBEC3G activity in the host cure HIV or cause cancer?
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Keyworddelim
Apobec3g; Cancer; Dna Cytosine Deamination; Genomic Mutation; Hiv-1; Hypermutation; Mutagenesis; Nuclear Localization; Retrovirus Restriction; Vif
Abstract
The human APOBEC3G protein has the potential to stop the spread of the AIDS virus, HIV. APOBEC3G's mechanism of lethality involves causing mutations of guanine to adenine in the proviral DNA, which is termed hypermutation. This can occur so frequently that APOBEC3G literally kills the virus. However, the full potential of APOBEC3G is rarely realized in patients because HIV fights back with its own protein called Vif, which binds APOBEC3G and triggers its degradation. This Vif/APOBEC3G interaction would therefore be promising to alter in favour of the host for therapeutic potential. There is however one very important potential downside to such an approach: too much APOBEC3G activity may generate cancer-causing mutations. I therefore hypothesize that there is a critical threshold of APOBEC3G activity that is managed normally by host cells, but activity above this critical level would allow APOBEC3G to enter the host nucleus and cause mutations that could promote cancer. To test this hypothesis, I will express a range of APOBEC3G protein levels in cell lines and primary cells and monitor APOBEC3G cellular localization (nucleus vs. cytoplasm). I will also assess the induction of genomic mutations by monitoring reporter gene expression in cell lines for identification of mutations that nullify expression and by identifying the immortalization of primary cells. The proposed research will determine the possibility of saturating the cell's APOBEC3G threshold. If it can be saturated, we expect that with increased APOBEC3G expression, the level of APOBEC3G in the nucleus will also increase, as will the level of genomic mutations. Before novel treatment strategies for HIV are considered that alter APOBEC3G activity or levels, it is imperative to elucidate if increasing APOBEC3G expression will send the promutagenic protein to the nucleus and cause genomic mutations, to help ensure that we do not accidentally design drugs that give people cancer (but cure HIV).
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Land, Allison M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~